References:
1. Cohen J, Normile D. New SARS-like virus in Chinatriggers alarm. AmericanAssociation for theAdvancement of Science; 2020.2. Zhu N ,Zhang D, Wang W, Li X, Yang B, Song J, et
al. A novel coronavirus from patients with pneumoniain China, 2019. New England Journal of Medicine.2020.3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al.Early transmission dynamics in Wuhan, China, ofnovel coronavirus–infected pneumonia. New EnglandJournal of Medicine. 2020.4. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.;He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; etal. Clinical Characteristics of Coronavirus Disease2019 in China. N. Engl. J. Med. 2020.5. Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.Y.; Chen,
L.; Wang, M. Presumed Asymptomatic CarrierTransmission of COVID-19. JAMA 2020.
6. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han,Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al.Epidemiological and clinical characteristics of 99cases of 2019 novel coronavirus pneumonia inWuhan, China: A descriptive study. Lancet 2020, 395,507–513.7. M. Zheng, Y. Gao, G. Wang, G. Song, S. Liu, D. Sun,Y. Xu, Z. Tian, Functional exhaustion of antiviral
lymphocytes in COVID-19 patients, Cell MolImmunol. (2020), tps://doi.org/10.1038/s41423-020-0402-2.8. Rothe C, Schunk M, Sothmann P, et al. Transmissionof 2019- nCoV infection from an asymptomaticcontact in Germany. N Engl J Med. 2020.https://doi.org/10.1056/NEJMc20014689. Jin YH, Cai L, Cheng ZS, et al. A rapidadviceguideline for the diagnosis and treatment of 2019novel coronavirus [2019-nCoV] infected pneumonia[standard version]. Mil Med Res. 2020; 7:4.10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.Clinical characteristics of 138 hospitalized patientswith 2019 novel coronavirus–infected pneumonia inWuhan, China. Jama. 2020.11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.Clinical features of patients infected with 2019 novel
coronavirus in Wuhan ,China. The Lancet.2020;395(10223):497-506.12. Petrovska BB. Historical review of medicinal plants’usage. Pharmacognosy reviews. 2012;6(11):1.
13. Eshwarappa RSB, Iyer S, Subaramaihha SR,Richard SA, Dhananjaya BL. Antioxidant activities ofFicus glomerata (moraceae) leaf gall extracts.Pharmacognosy research. 2015;7(1):114.14. Saleem A, Husheem M, Härkönen P, Pihlaja K.Inhibition of cancer cell growth by crude extract andthe phenolics of Terminalia chebula retz. fruit. Journalof Ethnopharmacology. 2002;81(3):327-36.15. Belapurkar P, Goyal P, Tiwari-Barua P.
Immunomodulatory effects of triphala and itsindividual constituents: a review. Indian journal ofpharmaceutical sciences. 2014;76(6):467.16. Gupta PC. Biological and pharmacological
properties of Terminalia chebula Retz.(Haritaki)-Anoverview. Int J pharm pharm Sci. 2012;4(Suppl 3):62-8.17. Jokar A, Masoomi F, Sadeghpour O, Nassiri-Toosi
M, Hamedi S. Potential therapeutic applications forTerminalia chebula in Iranian traditional medicine.Journal of Traditional Chinese Medicine.2016;36(2):250-4.18. Vonshak A, Barazani O, Sathiyamoorthy P, ShalevR, Vardy D, Golan‐ Goldhirsh AJPRAIJDtP, et al.
Screening South Indian medicinal plants forantifungal activity against cutaneous pathogens.
2003;17(9):1123-5.19. Malekzadeh F, Ehsanifar H, Shahamat M, Levin M,Colwell R. Antibacterial activity of black myrobalan(Terminalia chebula Retz) against Helicobacter pylori.International journal of antimicrobial agents.2001;18(1):85-8.
20. Ghosh A, Das BK, Roy A, Mandal B, Chandra G.Antibacterial activity of some medicinal plantextracts. Journal of natural medicines.2008;62(2):259-62.21. Kannan P, Ramadevi S, Hopper W. Antibacterialactivity of Terminalia chebula fruit extract. African
Journal of Microbiology Research. 2009;3(4 :)081-4.22. Nagar S, Belapurkar P, Barua PT, Goyal P.Antimicrobial and phytochemical analysis of Triphalaand comparison with its individual constituents. NatlJ Life Sci. 2011;8:101-3.23. Ma H, Diao Y, Zhao D, Li K, Kang T. A newalternative to treat swine influenza A virus infection:extracts from Terminalia chebula Retz. Afr JMicrobiol Res. 2010;4(6):497-9.24. Yukawa TA, Kurokawa M, Sato H, Yoshida Y,Kageyama S, Hasegawa T, et al. Prophylactictreatment of cytomegalovirus infection withtraditional herbs. Antiviral research. 1996;32(2):63-70.
25. Kim TG, Kang SY, Jung KK, Kang JH, Lee E, HanHM, et al. Antiviral activities of extracts isolated fromTerminalis chebula Retz., Sanguisorba officinalis L.,
Rubus coreanus Miq. and Rheum palmatum L. agains 07hepatitis B virus. Phytotherapy research.2001;15(8):718-20.26. Yukawa TA, Kurokawa M, Sato H, Yoshida Y,Kageyama S, Hasegawa T, et al. Prophylactictreatment of cytomegalovirus infection withtraditional herbs. 1996;32(2):63-70.27. Ahn M-J, Kim CY, Lee JS, Kim TG, Kim SH, LeeC-K, et al. Inhibition of HIV-1 integrase by galloylglucoses from Terminalia chebula and flavonolglycoside allates from Euphorbia pekinensis. PlantaMedica. 2002;68(05):457-9.28. Lin L-T, Chen T-Y, Lin S-C, Chung C-Y, Lin T-C,Wang G-H, et al. Broad-spectrum antiviral activity ofchebulagic acid and punicalagin against viruses thatuse glycosaminoglycans for entry. BMCmicrobiology. 2013;13(1):187.29. Arruzazabala MdL, Carbajal D, Mas R, Molina V,Valdes S, Laguna A. Cholesterol-lowering effects ofpolicosanol in rabbits. Biological research. 1994;27(3-
4):205-8.30. Ledon N, Casaco A, Rodriguez V, Cruz J, GonzalezR, Tolon Z, et al. Anti-inflammatory and analgesiceffects of a mixture of fatty acids isolated and purifiedfrom sugar cane wax oil. Planta medica.2003;69(04):367-9.31. Jin Y, Liang H, Cao C, Wang Z, Shu R, Li X.Immunological activity of bagasse polysaccharides(author's transl). Zhongguo yao li xue bao= Actapharmacologica Sinica. 1981;2(4):269.32. Sakai Y, Sato M, Funami Y, Ishiyama A, Hokari R,Iwatsuki M, et al. Peyer's patch-immunomodulatingglucans from sugar cane enhance protective immunitythrough stimulation of the hemopoietic system. Int JBiol Macromol. 2019;124:505-14.33. Dabos KJ, Sfika E, Vlatta LJ, Giannikopoulos G.The effect of mastic gum on Helicobacter pylori: arandomized pilot study. Phytomedicine. 2010;17(3-
4):296-9.34. Dimas KS, Pantazis P, Ramanujam R. Chios masticgum: a plant-produced resin exhibiting numerousdiverse pharmaceutical and biomedical properties. invivo. 2012;26(5):777-85.35. Mahmoudi M, Ebrahimzadeh M, Nabavi S, HafeziS, Nabavi S, Eslami SJERMPS. Antiinflammatoryand antioxidant activities of gum mastic.2010;14(9):765-9.36. Zhou L, Satoh K, Takahashi K, Watanabe S,Nakamura W, Maki J, et al. Re-evaluation of anti-inflammatory activity of mastic using activatedmacrophages. 2009;23(4):583 -9.37. Papada E, Amerikanou C, Torović L,Kalogeropoulos N, Tzavara C, Forbes A, et al. Plasmafree amino acid profile in quiescent InflammatoryBowel Disease patients orally administered withMastiha (Pistacia lentiscus); a randomised clinicaltrial. Phytomedicine. 2019;56:40-7.38. Lopez H, Habowski S, Sandrock J, Raub B, KediaA, Bruno E, et al. Effects of dietary supplementationwith a standardized aqueous extract of Terminalia
chebula fruit (AyuFlex®) on joint mobility, comfort,and functional capacity in healthy verweightsubjects: a randomized placebo-controlled clinicaltrial. BMC complementary and alternative medicine.2017;17(1):475.39. Papada E, Gioxari A, Amerikanou C, Forbes A,
Tzavara C, Smyrnioudis I, et al. Regulation of faecalbiomarkers in inflammatory bowel isease patientstreated with oral mastiha (Pistacia lentiscus)supplement: A double‐blind and placebo‐ controlledrandomised trial. Phytotherapy research.2019;33(2):360-9.40. Papada E, Forbes A, Amerikanou C, Torović L,Kalogeropoulos N, Tzavara C, et al. Antioxidativeefficacy of a Pistacia lentiscus supplement and itseffect on the plasma amino acid profile inInflammatory Bowel Disease: A randomised, double-blind, placebo-controlled trial. Nutrients.2018;10(11):1779.41. Gouni-Berthold I, Berthold HK. Policosanol:clinical pharmacology and therapeutic significance ofa new lipid-lowering agent. American heart journal.2002;143(2):356-65